Rosuvastatin 10mg tablets recalled for manufacturing process deviations
RemedyRepack Inc. is recalling Rosuvastatin 10mg tablets due to cGMP deviations in the manufacturing process. The recall affects 30-count and 90-count bottles distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recalls indicate serious health risk is possible though not probable. No illnesses or injuries have been reported. The cGMP deviations represent a quality control issue rather than a confirmed product hazard.
Plain-English summary
RemedyRepack Inc. is recalling Rosuvastatin 10mg tablets in both 30-count bottles (NDC 70518-0375-03 and 70518-0375-01) and 90-count bottles (NDC 70518-0375-00).
The recall was initiated on March 20, 2023, due to cGMP (current Good Manufacturing Practice) deviations in the manufacturing and repackaging process. The firm voluntarily initiated this recall.
A total of 399 bottles of the 30-count product and 445 bottles of the 90-count product were distributed nationwide by RemedyRepack to consignees throughout the United States. Specific lot numbers and expiration dates for affected batches are documented in the recall notice.
The FDA classified this as a Class II recall, and the recall was terminated on October 19, 2023.
The recalled product
- Product
- Rosuvastatin 10mg tablets, packaged in a) 30-count bottles (NDC 70518-0375-03 and 70518-0375-01) and b) 90-count bottles (NDC 70518-0375-00), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701.
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Statin
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Lot#: a) NDC 70518-0375-03: J0674788-011123
- Exp. Date 01/31/2024
- J0664118-112922 J0664118-112922
- Exp. Date 12/31/2023
- J0653727-101722
- Exp. Date 10/31/2023. NDC 70518-0375-01: B2057931-011223
- Exp. Date 07/31/2025 b) Lot #: B2075815-012523
- Exp. Date 09/30/2025
- B2011634-121322
- Exp. Date 07/31/2025 B1970205-112022
- Exp. Date 06/30/2024
- B1862598-092022
- Exp. Date 03/31/2024
- B2077226-012523
- B2070444-012023
- Exp. Date 07/31/2025.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 14 recalled by RemedyRepack Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 14 products in this recall →Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · cGMP deviation
See all →- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateIndomethacin Extended-Release Capsules recalled for cGMP deviations
FDA (Drugs) · 2025-06-11
- SevereLubricant Eye Drops Solution recalled due to sterility assurance concerns
FDA (Drugs) · 2025-05-14